J&J Gains On Revising Guidance After Medical Devices Boost In Q2



© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:) stock was up 1.2% in Wednesday’s premarket trading as the company raised its full-year guidance for sales and earnings after a robust second quarter.

The company benefited a little from its COVID-19 vaccine and much more from its medical devices business, which boomed as hospitals resumed the medical procedures they had delayed during the pandemic.

The company’s consumer health business grew 10%, pharmaceutical operations 14% while medical devices rose 59%.

The company expects full-year sales of $93.8 billion to $94.6 billion including $2.5 billion-contribution from its COVID-19 vaccine. Discounting the COVID-19 jab, it still translates into growth of 10.5%-11.5%.

Overall annual adjusted diluted earnings per share are seen at $9.60-$9.70.

Second-quarter adjusted diluted EPS came at $2.48 on sales of $23.31 billion. Both numbers were higher than the estimated $2.29 and $22.5 billion, respectively.

The company’s forecast of $2.5 billion in revenue from sales of COVID-19 vaccines is in stark contrast to Pfizer ‘s (NYSE:) estimation of $26 billion and Moderna ‘s (NASDAQ:) $19.2 billion. 

Both companies have said they expect to profit from their vaccines, while J&J has said it will make its shots available on a not-for-profit basis during the pandemic, according to Reuters.

 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

See also  Alphabet settles shareholder suit over sexual misconduct cases

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here